New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
NCT ID NCT07612904
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a treat-and-extend schedule for aflibercept eye injections works better than the standard as-needed approach for people with diabetic macular edema who have not had prior treatment. About 186 participants will receive three monthly injections, then either extend the time between injections based on eye health or get injections only when fluid returns. The main goal is to see which schedule leads to better vision after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept (Zhuochuming®) eye injection
- What this could lead to
- If successful, this could show that a treat-and-extend schedule works as well as or better than the standard as-needed approach, potentially reducing the number of injections needed over time.
- What could go wrong
- This is a phase 4 trial, so the drug is already approved. However, the treat-and-extend regimen may not prove superior, and some patients may still need frequent injections. Eye injections carry risks like infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Third Peoples Hospital of Dalian
Dalian, Liaoning, 1160033, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New syringe could simplify High-Dose eye treatment
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy
- New hope for diabetes-related vision loss: experimental drug faces final test